TMPRSS2 and Familial prostate cancer: TDRD1 has been discovered to be a direct target of (ETS-related gene) ERG, which promotes tumor initiation and progression in TMPRSS2-ERG fusion prostate cancer and could be a new immunotherapy target (40–42).